RxDoctor Payments Data

Barry Landfield, MD

Family Medicine · Greenbrae, CANPI 1386735058

Payments from drug & device makers

$6,967in general payments, 2019–2025

Across 362 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Esperion Therapeutics, Inc.$1K
  • Lilly USA, LLC$616
  • AstraZeneca$599
  • Boehringer Ingelheim$529
  • AbbVie$397
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$6,940100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,967 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$119,378
Medicare patients
242
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$169,583
JardianceEmpagliflozin75$96,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$56,413
TriumeqAbacavir/Dolutegravir/Lamivudi12$45,204
RybelsusSemaglutide24$44,896
FarxigaDapagliflozin Propanediol49$42,427
EliquisApixaban29$35,899
XareltoRivaroxaban28$33,604
KerendiaFinerenone18$19,228
NexlizetBempedoic Acid/Ezetimibe21$13,669
OxycontinOxycodone Hcl16$12,575
Fosamprenavir Calcium12$10,583
Atorvastatin Calcium685$8,405
Ezetimibe208$5,874
Levothyroxine Sodium251$4,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,579$214,479169 claims
Boehringer IngelheimJardiance$529$96,03175 claims
GSKTrelegy Ellipta$230$56,41356 claims
AstraZenecaFarxiga$599$42,42749 claims
PfizerEliquis$24$35,89929 claims
Johnson & JohnsonXarelto$56$33,60428 claims
BayerKerendia$286$19,22818 claims
Esperion Therapeutics, Inc.Nexlizet$1,238$13,66921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Greenbrae

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →